Sudarshan Paramsothy

Dr Sudarshan Paramsothy is an academic researcher specializing in gastrointestinal diseases, particularly inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. His work focuses on microbiota-based therapies, such as fecal microbiota transplantation (FMT), and optimizing treatment strategies involving biological agents and immunomodulators. He leads the Persistence Australian National IBD Cohort (PANIC) studies and the Australia IBD Microbiome (AIM) study, investigating microbiome dynamics, therapeutic efficacy, and clinical outcomes. His research spans pharmacokinetics of biologics, histological assessments, and real-world treatment persistence. He has contributed to international consensus guidelines on FMT and microbiome testing, and his studies address gaps in understanding disease mechanisms and improving patient care through translational research.

• Key Research: FMT efficacy, microbial strain engraftment, biomarker development
• Grants: NHMRC Investigator Grant for FMT and microbial therapy research
• Collaborations: Multinational studies on IBD epidemiology, treatment outcomes, and microbiome analysis